Neurology

Phase 3 data show oral fenebrutinib slows primary progressive multiple sclerosis disability progression versus ocrelizumab, with early upper-limb gains and a manageable safety profile.

Amid a lack of research on their specific perspectives, women with epilepsy share their experiences with pregnancy and reproductive health.

Novo Nordisk announced results of the evoke and evoke+ phase 3 trials on semaglutide’s use in treating Alzheimer disease progression.

The CDC states that the claim “vaccines do not cause autism” is not evidence based because studies have not ruled out the possibility that infant vaccines cause autism.

Older adults with dementia face significantly higher COVID-19 risks, highlighting the need for targeted health strategies during pandemics.

Pain medication expert Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, joined Drug Topics to explore the referenced studies in the Trump Administration’s push to link acetaminophen use with autism.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, also known as “the Pain Guy,” discusses his initial reactions upon learning about the Trump Administration linking acetaminophen use with autism.

As part of this announcement, the administration launches initiatives across the National Institutes of Health, the FDA, and the Center for Medicare & Medicaid Services.

FDA approves Leqembi's subcutaneous formulation, enhancing accessibility for Alzheimer treatment and paving the way for future combination therapies.

Investigators find this association primarily affects female patients when compared with male patients.

Currently, systemic estrogen replacement therapy is contraindicated for women who have a history of ischemic stroke due to the risk of stroke recurrence.

DTC pharmacies offer significant savings on total medication costs for neurological drugs, but out-of-pocket expenses remain high for insured patients.

New research shows metformin's inconsistent neuroprotective effects against Alzheimer disease, challenging its role in diabetes management for cognitive health.

In this retrospective cohort study, researchers investigated the association between formulary coverage for disease-modifying therapies and the potential for MS relapse.

Community pharmacies emerge as key players in early cognitive decline detection, offering vital screening tools and support for at-risk patients.

Patients with a single cardiometabolic disease have an approximately 48% greater risk of developing all-cause dementia than those without a cardiometabolic disease.

In the study, the composition of the gut microbiome could also be affected by food insecurity, a known social determinant of health.

Researchers investigated Norwegian pharmacists to understand their expertise, and potential knowledge gaps, regarding issues of epilepsy and treatment using antiseizure medication.

PET and autopsy assays suggest that Alzheimer disease (AD) and non-AD tau pathologies could be the underlying cause of some late-life mood disorders.

Although there is no cure for MS, treatment focuses on recovery from attacks, reducing relapse, slowing disease progression, and managing multiple sclerosis symptoms.

Triptans are often a first-line treatment for migraine and can be used to treat menstrual migraine and cluster headaches.

However, there is no association between cortisol and tau pathology.

Dihydroergotamine (Brekiya) is an acute treatment to help relieve migraine attacks, and it can come in nasal sprays, injections, and intravenous infusions.

The drug is approved for the short-term treatment of acute repetitive seizures, also known as seizure clusters, which differ from a patient’s normal seizure pattern.

The drug is also approved for adults with chronic inflammatory demyelinating polyneuropathy.